Literature DB >> 16846786

Lysophosphatidic acid cooperates with 1alpha,25(OH)2D3 in stimulating human MG63 osteoblast maturation.

J Gidley1, S Openshaw, E T Pring, S Sale, J P Mansell.   

Abstract

Osteoblast maturation is partly controlled by the interaction of 1alpha,25(OH)(2)D(3) (D3), an active metabolite of Vitamin D, with other growth factors. The first reports describing the in vitro effect of D3 on human osteoblast differentiation performed experiments in the presence of serum. One potentially exciting candidate that might help explain the D3 responses observed for osteoblasts cultured with serum is lysophosphatidic acid (LPA). Drawn to the possibility that D3 and serum borne LPA might interact to induce osteoblast maturation we co-treated human cells with D3 and serum in the presence of Ki16425, an LPA receptor antagonist. Ki16425 inhibited osteoblast maturation as determined by markedly reduced alkaline phosphatase (ALP) expression. We subsequently found that LPA and D3 acted synergistically in generating mature osteoblasts and that this differentiation response could be inhibited using pertussis toxin, implying an important role of Galphai signal transduction. Furthermore, we found evidence for a dependency on both mitogen activated protein kinase kinase (MEK) and Rho associated coiled kinase (ROCK) for LPA and D3 stimulated maturation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16846786     DOI: 10.1016/j.prostaglandins.2006.04.001

Source DB:  PubMed          Journal:  Prostaglandins Other Lipid Mediat        ISSN: 1098-8823            Impact factor:   3.072


  16 in total

1.  FGF23 gene regulation by 1,25-dihydroxyvitamin D: opposing effects in adipocytes and osteocytes.

Authors:  Ichiro Kaneko; Rimpi K Saini; Kristin P Griffin; G Kerr Whitfield; Mark R Haussler; Peter W Jurutka
Journal:  J Endocrinol       Date:  2015-07-06       Impact factor: 4.286

Review 2.  [Research progress on the biological regulatory function of lysophosphatidic acid in bone tissue cells].

Authors:  Xiang-Nan Wu; Yuan-Yuan Ma; Zhi-Chao Hao; Hang Wang
Journal:  Hua Xi Kou Qiang Yi Xue Za Zhi       Date:  2020-06-01

3.  Development and biological evaluation of fluorophosphonate-modified hydroxyapatite for orthopaedic applications.

Authors:  Gráinne Neary; Ashley W Blom; Anna I Shiel; Gabrielle Wheway; Jason P Mansell
Journal:  J Mater Sci Mater Med       Date:  2018-07-21       Impact factor: 3.896

4.  Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations.

Authors:  Saida Mebarek; Abdelkarim Abousalham; David Magne; Le Duy Do; Joanna Bandorowicz-Pikula; Slawomir Pikula; René Buchet
Journal:  Int J Mol Sci       Date:  2013-03-01       Impact factor: 5.923

5.  Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic acid-dependent activation of osteoclasts.

Authors:  Marion David; Estelle Wannecq; Françoise Descotes; Silvia Jansen; Blandine Deux; Johnny Ribeiro; Claire-Marie Serre; Sandra Grès; Nathalie Bendriss-Vermare; Mathieu Bollen; Simone Saez; Junken Aoki; Jean-Sébastien Saulnier-Blache; Philippe Clézardin; Olivier Peyruchaud
Journal:  PLoS One       Date:  2010-03-17       Impact factor: 3.240

6.  Lysophosphatidic acid receptor type 1 (LPA1) plays a functional role in osteoclast differentiation and bone resorption activity.

Authors:  Marion David; Irma Machuca-Gayet; Junichi Kikuta; Penelope Ottewell; Fuka Mima; Raphael Leblanc; Edith Bonnelye; Johnny Ribeiro; Ingunn Holen; Rùben Lopez Vales; Pierre Jurdic; Jerold Chun; Philippe Clézardin; Masaru Ishii; Olivier Peyruchaud
Journal:  J Biol Chem       Date:  2014-01-15       Impact factor: 5.157

7.  Vitamin D receptor-dependent 1 alpha,25(OH)2 vitamin D3-induced anti-apoptotic PI3K/AKT signaling in osteoblasts.

Authors:  Xiaoyu Zhang; Laura P Zanello
Journal:  J Bone Miner Res       Date:  2008-08       Impact factor: 6.741

8.  Fluorophosphonate-functionalised titanium via a pre-adsorbed alkane phosphonic acid: a novel dual action surface finish for bone regenerative applications.

Authors:  Wayne Nishio Ayre; Tom Scott; Keith Hallam; Ashley W Blom; Stephen Denyer; Heather K Bone; Jason P Mansell
Journal:  J Mater Sci Mater Med       Date:  2015-12-24       Impact factor: 3.896

9.  Absence of the lysophosphatidic acid receptor LPA1 results in abnormal bone development and decreased bone mass.

Authors:  Isabelle Gennero; Sara Laurencin-Dalicieux; Françoise Conte-Auriol; Fabienne Briand-Mésange; Danielle Laurencin; Jackie Rue; Nicolas Beton; Nicole Malet; Marianne Mus; Akira Tokumura; Philippe Bourin; Laurence Vico; Gérard Brunel; Richard O C Oreffo; Jerold Chun; Jean Pierre Salles
Journal:  Bone       Date:  2011-05-01       Impact factor: 4.398

10.  LPA-induced suppression of periostin in human osteosarcoma cells is mediated by the LPA(1)/Egr-1 axis.

Authors:  Werner Windischhofer; Evelyn Huber; Christine Rossmann; Michaela Semlitsch; Kerstin Kitz; Anamaria Rauh; Trevor Devaney; Hans-Jörg Leis; Ernst Malle
Journal:  Biochimie       Date:  2012-05-29       Impact factor: 4.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.